What happened in this Health story?

The FDA told a federal court its safety review of mifepristone will extend into next year, with a study completing by mid-December and a final report due no later than March 2027, before any new restrictions on the abortion pill are considered.

What is a key fact in this story? (1)

**FDA** told a federal court its safety review of mifepristone will continue into next year, providing the first substantive update on a reevaluation ordered by Health Secretary Robert F. Kennedy Jr.

What is a key fact in this story? (2)

**The agency** expects to complete its safety study by mid-December 2025, with a report on findings due "no later than March 2027," after which it will decide whether to impose new restrictions or other changes on the drug.

📎 SkimNews has covered FDA 85+ times · see the file →

FDA says its safety review of abortion pill will continue into next year — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-08

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

FDA told a federal court its safety review of mifepristone will continue into next year, providing the first substantive update on a reevaluation ordered by Health Secretary Robert F. Kennedy Jr.
The agency expects to complete its safety study by mid-December 2025, with a report on findings due "no later than March 2027," after which it will decide whether to impose new restrictions or other changes on the drug.
FDA said it is using a "statistical data mining method" drawing from an electronic database of medical injuries and drug side effects reported by major health networks and insurers to discover any "unknown safety concerns."
Gavin Oxley of anti-abortion group Americans United for Life criticized the timeline as a lack of "true leadership," saying the administration is "clearly uninterested in mitigating the ongoing harms caused by the abortion pill."
The mifepristone review stems from a Louisiana lawsuit alleging that mail-delivery of the drug undermines the state's abortion ban; a three-judge 5th Circuit panel last month questioned the state's legal standing to challenge FDA oversight.
Anti-abortion groups have focused their pressure on the 2021 decision allowing doctors to prescribe mifepristone online and ship it by mail during COVID-19, made permanent under Biden in 2023, which effectively undermined several state abortion bans.
Supreme Court has blocked any changes to mifepristone's access until it sees the case again, meaning any ruling from the 5th Circuit on Louisiana's case would not immediately alter the drug's availability.

Why it matters: The timeline pushes any new FDA restrictions on mifepristone — the drug used in the most common form of U.S. abortion — to no earlier than March 2027, frustrating anti-abortion allies who backed the Trump-era review. The agency's use of post-market injury "data mining" to hunt for safety signals differs from its prior approach of re-affirming the pill's safety since its 2000 approval.